CoChat

Editorial Commentary:Interferon‐γ Release Assays: What Is Their Role in the Diagnosis of Active Tuberculosis?

Pai, Madhukar, Menzies, Dick · 2007 · Clinical Infectious Diseases
Cited by 90

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Until recently, the only tool available to detect latent tuberculosis infection (LTBI) was the tuberculin skin test (TST). Although the TST has proven to be useful in clinical practice, it has known limitations [1]. An important advance in recent years has been the development of in vitro T cell—based IFN-γ release assays (IGRAs). These assays use antigens more specific to Mycobacterium tuberculosis than the PPD used in the TST. As reviewed elsewhere [2, 3], there is now considerable evidence that prior bacille Calmette-Guárin vaccination does not affect IGRA results, meaning that IGRAs have higher specificity than does the TST. Besides the high specificity, other potential advantages of IGRAs include logistical convenience, avoidance of subjective measurements (such as skin induration), need for fewer patient visits, and the ability to perform serial testing without inducing the boosting phenomenon. Although IGRAs are promising for LTBI diagnosis and are being used in place of the TST in some settings, what is their potential role in the evaluation of individuals with suspected active tuberculosis? There are 2 reasons for evaluating IGRAs among patients with active tuberculosis: (1) to use active tuberculosis as a surrogate reference standard for LTBI (most published studies would fit in this category), and (2) to determine whether IGRAs will be helpful in diagnosing active tuberculosis, per se. Both approaches have limitations. The first reason is based on the logic that anyone with active tuberculosis must have tuberculosis infection—albeit not latent infection. Therefore, the assumption is that active tuberculosis is an acceptable surrogate for LTBI, which may or may not be valid. From an immunological perspective, active tuberculosis occurs when the host immune response is unable to contain the latent infection; thus, it is possible that the sensitivity of IGRAs in active disease may not reflect their sensitivity in LTBI. The second reason to perform the test is based on the assumption that evidence of tuberculosis infection (i.e., a positive IGRA result) is useful to diagnose active disease. This is problematic, because IGRAs, like the TST, are based on cellular immune response, and as such, they are incapable of distinguishing between LTBI and active disease. This is an issue because most cases of tuberculosis disease occur in populations with a high prevalence of LTBI. It has been suggested that IGRAs have the potential to serve as useful tests to rule out active tuberculosis in selected populations (e.g., children and immunocompromised persons) in which microbiologic diagnosis is hard to establish [3, 4]. In other words, although a positive IGRA result may not always indicate active disease, a negative IGRA result may indicate lack of tuberculosis infection and, therefore, of disease. For IGRAs to be useful in excluding active disease, they must be highly sensitive in patients with active tuberculosis. In this issue of Clinical Infectious Diseases, Dewan et al. [5] suggest that this may not always be the case for the QuantiFERON-TB Gold (QFT-G; Cellestis) assay. Their study estimated the sensitivity of QFT-G among individuals with suspected tuberculosis disease in San Francisco. They found that only 64% (95% CI, 48%–78%) of 36 patients with culture-positive tuberculosis had positive QFT-G results [5]. These data, although limited by a small number of patients (reflected in the imprecision of their sensitivity estimate) and lack of a prospective head-to-head comparison with TST, add to the growing body of literature on the sensitivity of QFT-G in various populations. Table 1 and figure 1 present the results of 10 published studies of QFT-G among patients with active tuberculosis [5–14]. Most studies recruited patients with microbiologically confirmed tuberculosis disease who were untreated or who received treatment for <4 weeks. A majority of these studies, including the study by Dewan et al. [5], used the second-generation QFT-G assay, which is currently licensed in the United States and has been approved by the US Food and Drug Administration. This second-generation version has already been replaced in many countries by the newer “In Tube” version of the assay (currently under US Food and Drug Administration review). The In Tube assay is simpler to use and may be more sensitive than the second-generation format [15]. Data from 10 studies of QuantiFERON-TB Gold (QFT-G; Cellestis) among individuals with active tuberculosis (TB). Forest plot of studies on sensitivity of QuantiFERON-TB Gold (Cellestis) among individuals with active tuberculosis in 10 studies. Point estimates of sensitivity from each study are shown as solid squares with 95% CIs. The pooled sensitivity estimate (diamond) is shown at the bottom with the 95% CI (corrected for overdispersion). Indeterminate results were not excluded for the calculation of sensitivity estimates. As seen in figure 1, the sensitivity (conservatively estimate

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/509927

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 90

Metadata

Authors
Pai, M., & Menzies, D.
Venue
Clinical Infectious Diseases
Published
2007-01
Volume
44
Issue
1
Pages
74-77
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W1843608699
Cited by
90
References
1
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Editorial Commentary:Interferon‐γ Release Assays: What Is Their Role in the Diagnosis of Active Tuberculosis? https://app.cochat.ai/papers/10.1086/509927
The paper
Pai, M., & Menzies, D. (2007). Editorial Commentary:Interferon‐γ Release Assays: What Is Their Role in the Diagnosis of Active Tuberculosis? Clinical Infectious Diseases. https://doi.org/10.1086/509927

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.